Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

Uenishi, Takahiro; Kubo, Shoji; Hirohashi, Kazuhiro; Tanaka, Hiromu; Shuto, Taichi; Yamamoto, Takatsugu; Nishiguchi, Shuhei

doi:10.1038/sj.bjc.6601026

Cited by 64 publications

(42 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding may also support the notion that CA-125 is of mesothelial rather than tumoral origin. This is consistent with the findings in previous studies (Bergmann et al 1987;Zeimet et al 1996;Epiney et al 2000;Sjoval et al 2002;Miralles et al 2003;Uenishi et al 2003).…”

Section: Discussionsupporting

confidence: 83%

“…To increase the sensitivity of the peritoneal fluid study, several tumor markers have been analysed (Sarı 2001;Kiluk et al 2002;Sedlaczek et al 2002;Sehouli et al 2003;Uenishi et al 2003). Besides, the development of a peritoneal malignancy is frequently associated with high blood levels of tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen-125 (CA-125), carbohydrate antigen-19.9 (CA-19.9), carbohydrate antigen-15.3 (CA-15.3) and ferritin.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Usefulness of Carbohydrate Antigen-125 in Cancerous and Noncancerous Peritoneal Effusions

Kemer

Örmen

Kuralay

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Carbohydrate antigen-125 (CA-125) is a tumor marker that has been used for differential diagnosis of peritoneal malignancies. The aim of the present study was to evaluate the diagnostic usefulness of simultaneous quantification of CA-125 in peritoneal fluid and serum for abdominal cancer cases and noncancer diseases. Noncancer disease group included cirrhotic patients (n = 28) and spontaneous bacterial peritonitis (SBP) patients (n = 11). Abdominal cancer group was composed of histologically diagnosed various malignancies (n = 10), such as gastric cancer. CA-125 levels were quantified by chemiluminescent enzyme immunoassay. Diagnostic usefulness tests and receiver operating characteristics (ROC) curve analysis were performed for the levels of peritoneal fluid CA-125 (pCA-125) and serum , and the ratio of pCA-125 to sCA-125 (p/sCA-125). The sCA-125 levels were significantly higher in noncancer patients than those in the cancer patients, while the pCA-125 levels showed no significant difference between the two groups. Notably, the p/sCA-125 ratio was significantly lower in the noncancer patients than that in the cancer patients. Area under the ROC curve was 0.267 for sCA-125, 0.542 for pCA-125 and 0.831 for p/sCA-125. The accepted cutoff values were the combination of values that gave the greatest diagnostic sensitivity plus specificity. Either sCA-125 or pCA-125 value gave lower diagnostic accuracy, whereas p/sCA-125 value demonstrated a significantly higher diagnostic accuracy (sensitivity-specificity pairs: 0.40-0.33 for sCA-125, 0.60-0.54 for pCA-125, and 0.80-0.72 for p/sCA-125, respectively). Hence, determination of p/sCA-125 improves the biochemical discrimination of abdominal cancerous cases from noncancerous diseases.carbohydrate antigen-125(CA-125); cirrhosis; spontaneous bacterial peritonitis; cancer; peritoneal effusion

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Patientsmentioning

confidence: 99%

Diagnostic Usefulness of Carbohydrate Antigen-125 in Cancerous and Noncancerous Peritoneal Effusions

Kemer

Örmen

Kuralay

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Thus, the screening for HCC is useful in detecting ICC in patients with chronic hepatitis C although the effectiveness of tumor marker measurement is unclear. Recently, we found the serum concentration of cytokeratin-19 fragments (CYFRA 21-1) to be useful as a diagnostic test for ICC, although the role of CYFRA 21-1 in screening has not yet been established [27]. Development of specific markers for ICC would considerably facilitate screening for ICC.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic Characteristics of Hepatitis C Virus-Associated Intrahepatic Cholangiocarcinoma

et al. 2005

View full text Add to dashboard Cite

Background: Although hepatitis C virus (HCV) infection is a possible pathogenetic factor for intrahepatic cholangiocarcinoma (ICC), clinicopathologic features of ICC patients with HCV infection remain unclear. Patients and Methods: Of 50 patients with ICC treated, 19 were infected with HCV (HCV-positive group) and 38 underwent surgical treatment. Clinicopathologic features and postoperative outcome were compared between patients with and without HCV infection. Results: In 15 patients in the HCV-positive group, ICC was detected during follow-up for chronic hepatitis C. The proportion of patients who underwent curative resection was significantly higher in the HCV-positive than in the HCV-negative group, and tumors were significantly smaller in the HCV-positive than in the HCV-negative group. In the HCV-positive group, tumors were significantly smaller in patients who were followed up for chronic hepatitis C than in patients who were not followed up. Although cumulative survival rates did not differ significantly between groups, prognoses of patients with small ICC were significantly better than those with large ICC. Conclusion: Follow-up for patients with chronic hepatitis C by imaging series at regular intervals is important and provides the possibility to detect a small ICC as well as a hepatocellular carcinoma. Resection should be guided by liver function and the tumor stage in patients with HCV-associated ICC.

show abstract

“…The neuron-specific enolase (NSE) is a highly specific marker for neurons (10), with its serum level being a potentially useful marker for the detection of tumors of neuronal origin (11,12). Cytokeratin 19 (CYFRA21-1) is another useful tumor marker employed in the diagnosis of various types of cancer (13)(14)(15), and is particularly sensitive in adenocarcinomas in the gastrointestinal tract and pancreas (13,16 (2,17). Combined with ultrasonography, AFP is the most common clinical approach to diagnosing hepatocellular carcinoma (18).…”

Section: Introductionmentioning

confidence: 99%

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Lü

Ren

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The present study aimed to assess the diagnostic/ prognostic value of various clinical tumor markers, including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 19 (CYFRA21-1), α-fetoprotein (AFP), carbohydrate antigen-125 (CA-125), carbohydrate antigen-19.9 (CA-19.9) and ferritin, individually or in combination. The electro-chemiluminescence immunization method was performed to detect the levels of seven tumor markers in 560 cancer patients and 103 healthy subjects for comparison. The serum levels of the seven markers measured in cancer patients were higher compared to healthy subjects (P<0.05 for AFP and P<0.001 for the remaining six markers). Different markers had different sensitivity towards different types of tumors. Combining more markers significantly increased the ratios of positive diagnosis in the tumors. The diagnostic sensitivities of combining seven markers were particularly high in digestive, urinary and skeletal tumors (82, 92 and 83%, respectively). Gynecological tumors have exhibited a constant yet relatively low positive diagnosis irrespective of the use of a single marker or combined markers. However, the increase in sensitivity when combining markers was accompanied by a decrease in specificity. Generally, combining more markers increased the tumor detection rates, while a combination of the seven markers provided the highest detection rate. Combined detection showed a particularly high sensitivity in detecting respiratory, digestive and urinary system tumors, with the lowest sensitivity observed in gynecological tumors. As a result, combining tumor markers may play an important role in early tumor detection/diagnosis while the loss of specificity can be tolerated.

show abstract

Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

Cited by 64 publications

References 55 publications

Diagnostic Usefulness of Carbohydrate Antigen-125 in Cancerous and Noncancerous Peritoneal Effusions

Diagnostic Usefulness of Carbohydrate Antigen-125 in Cancerous and Noncancerous Peritoneal Effusions

Clinicopathologic Characteristics of Hepatitis C Virus-Associated Intrahepatic Cholangiocarcinoma

Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment

Contact Info

Product

Resources

About